PMID- 36315242
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230409
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Print)
IS  - 0033-2917 (Linking)
VI  - 53
IP  - 4
DP  - 2023 Mar
TI  - Forecasting prognostic trajectories with mismatch negativity in early psychosis.
PG  - 1489-1499
LID - 10.1017/S0033291721003068 [doi]
AB  - BACKGROUND: Prognostic heterogeneity in early psychosis patients yields 
      significant difficulties in determining the degree and duration of early 
      intervention; this heterogeneity highlights the need for prognostic biomarkers. 
      Although mismatch negativity (MMN) has been widely studied across early phases of 
      psychotic disorders, its potential as a common prognostic biomarker in early 
      periods, such as clinical high risk (CHR) for psychosis and first-episode 
      psychosis (FEP), has not been fully studied. METHODS: A total of 104 FEP 
      patients, 102 CHR individuals, and 107 healthy controls (HCs) participated in 
      baseline MMN recording. Clinical outcomes were assessed; 17 FEP patients were 
      treatment resistant, 73 FEP patients were nonresistant, 56 CHR individuals were 
      nonremitters (15 transitioned to a psychotic disorder), and 22 CHR subjects were 
      remitters. Baseline MMN amplitudes were compared across clinical outcome groups 
      and tested for utility prognostic biomarkers using binary logistic regression. 
      RESULTS: MMN amplitudes were greatest in HCs, intermediate in CHR subjects, and 
      smallest in FEP patients. In the clinical outcome groups, MMN amplitudes were 
      reduced from the baseline in both FEP and CHR patients with poor prognostic 
      trajectories. Reduced baseline MMN amplitudes were a significant predictor of 
      later treatment resistance in FEP patients [Exp(beta) = 2.100, 95% confidence 
      interval (CI) 1.104-3.993, p = 0.024] and nonremission in CHR individuals [Exp(beta) 
      = 1.898, 95% CI 1.065-3.374, p = 0.030]. CONCLUSIONS: These findings suggest that 
      MMN could be used as a common prognostic biomarker across early psychosis 
      periods, which will aid clinical decisions for early intervention.
FAU - Kim, Minah
AU  - Kim M
AD  - Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Kim, Taekwan
AU  - Kim T
AD  - Department of Brain and Cognitive Sciences, Seoul National University College of 
      Natural Sciences, Seoul, Republic of Korea.
FAU - Hwang, Wu Jeong
AU  - Hwang WJ
AD  - Department of Brain and Cognitive Sciences, Seoul National University College of 
      Natural Sciences, Seoul, Republic of Korea.
FAU - Lho, Silvia Kyungjin
AU  - Lho SK
AD  - Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Moon, Sun-Young
AU  - Moon SY
AD  - Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Lee, Tae Young
AU  - Lee TY
AD  - Department of Neuropsychiatry, Pusan National University Yangsan Hospital, 
      Yangsan, Republic of Korea.
AD  - Institute of Human Behavioral Medicine, SNU-MRC, Seoul, Republic of Korea.
FAU - Kwon, Jun Soo
AU  - Kwon JS
AUID- ORCID: 0000-0002-1060-1462
AD  - Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Department of Psychiatry, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Department of Brain and Cognitive Sciences, Seoul National University College of 
      Natural Sciences, Seoul, Republic of Korea.
AD  - Institute of Human Behavioral Medicine, SNU-MRC, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210902
PL  - England
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Schizophrenia
MH  - Prognosis
MH  - Electroencephalography
MH  - *Psychotic Disorders
MH  - Logistic Models
MH  - Biomarkers
PMC - PMC10009395
OTO - NOTNLM
OT  - Clinical high risk
OT  - early psychosis
OT  - event-related potential
OT  - first-episode psychosis
OT  - mismatch negativity
OT  - prognostic marker
EDAT- 2021/09/02 00:00
MHDA- 2023/04/04 06:42
PMCR- 2023/03/13
CRDT- 2022/10/31 12:02
PHST- 2023/04/04 06:42 [medline]
PHST- 2021/09/02 00:00 [pubmed]
PHST- 2022/10/31 12:02 [entrez]
PHST- 2023/03/13 00:00 [pmc-release]
AID - S0033291721003068 [pii]
AID - 10.1017/S0033291721003068 [doi]
PST - ppublish
SO  - Psychol Med. 2023 Mar;53(4):1489-1499. doi: 10.1017/S0033291721003068. Epub 2021 
      Sep 2.